World journal of radiology · 2026
Diagnostic performance of magnetic resonance imaging-based radiomics for detecting prostate cancer: A systematic review and meta-analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhong Shi-Yu, Deng Xiang-Rong, Han Bang-Cai, Yang Liu-Qing, Ye Su-Ting, Niu Xiang-Ke
Аннотация
BACKGROUND: Prostate cancer (PCa) is the second most common malignancy and the fifth leading cause of cancer death among men worldwide. Magnetic resonance imaging (MRI)-based radiomics has emerged as a promising tool for diagnosing PCa, but its true potential remains a subject of ongoing debate.
AIM: To evaluate the diagnostic performance of MRI-based radiomics for PCa detection and compare it with the Prostate Imaging Reporting and Data System (PI-RADS) score.
METHODS: A systematic search of EMBASE, Web of Science, and PubMed was conducted up to August 18, 2025. Pooled sensitivity, specificity, and area under the curve were calculated. Subgroup analyses were performed to evaluate heterogeneity. Additionally, the diagnostic accuracy of MRI-based radiomics was compared with that of the PI-RADS score. Methodological quality was evaluated via the Radiomics Quality Score.
RESULTS: This meta-analysis included 49 studies encompassing 10512 patients. MRI-based radiomics demonstrated a pooled sensitivity of 0.84 [95% confidence interval (CI): 0.80-0.87], specificity of 0.78 (95%CI: 0.72-0.84), and area under the curve of 0.88 (95%CI: 0.85-0.91). Deek's funnel plot asymmetry test indicated no publication bias. Subgroup analyses revealed that multiparametric MRI-based radiomics is more effective in diagnosing clinically significant PCa and that 3D-based radiomics outperforms 2D approaches. In a head-to-head comparison, the MRI-radiomics model yielded a numerically greater pooled diagnostic value (0.85; 95%CI: 0.82-0.88) than did the PI-RADS score (0.71; 95%CI: 0.63-0.77) (P = 0.07). The mean Radiomics Quality Score was 18.2 (50.6% of the maximum score). All studies reported performing cut-off analyses, 22 studies (44.9%) addressed biological correlates, and all claimed code or data accessibility.
CONCLUSION: MRI-based radiomics is a reliable tool for detecting PCa, with 3D radiomic models showing greater effectiveness than 2D approaches in terms of sensitivity (0.85 vs 0.79). Radiomics also offers superior diagnostic accuracy for clinically significant PCa compared with the PI-RADS score, underscoring its potential in improving PCa diagnostics.
AIM: To evaluate the diagnostic performance of MRI-based radiomics for PCa detection and compare it with the Prostate Imaging Reporting and Data System (PI-RADS) score.
METHODS: A systematic search of EMBASE, Web of Science, and PubMed was conducted up to August 18, 2025. Pooled sensitivity, specificity, and area under the curve were calculated. Subgroup analyses were performed to evaluate heterogeneity. Additionally, the diagnostic accuracy of MRI-based radiomics was compared with that of the PI-RADS score. Methodological quality was evaluated via the Radiomics Quality Score.
RESULTS: This meta-analysis included 49 studies encompassing 10512 patients. MRI-based radiomics demonstrated a pooled sensitivity of 0.84 [95% confidence interval (CI): 0.80-0.87], specificity of 0.78 (95%CI: 0.72-0.84), and area under the curve of 0.88 (95%CI: 0.85-0.91). Deek's funnel plot asymmetry test indicated no publication bias. Subgroup analyses revealed that multiparametric MRI-based radiomics is more effective in diagnosing clinically significant PCa and that 3D-based radiomics outperforms 2D approaches. In a head-to-head comparison, the MRI-radiomics model yielded a numerically greater pooled diagnostic value (0.85; 95%CI: 0.82-0.88) than did the PI-RADS score (0.71; 95%CI: 0.63-0.77) (P = 0.07). The mean Radiomics Quality Score was 18.2 (50.6% of the maximum score). All studies reported performing cut-off analyses, 22 studies (44.9%) addressed biological correlates, and all claimed code or data accessibility.
CONCLUSION: MRI-based radiomics is a reliable tool for detecting PCa, with 3D radiomic models showing greater effectiveness than 2D approaches in terms of sensitivity (0.85 vs 0.79). Radiomics also offers superior diagnostic accuracy for clinically significant PCa compared with the PI-RADS score, underscoring its potential in improving PCa diagnostics.